These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38807104)

  • 21. Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
    Cai H; Xu B; Li N; Zheng B; Zheng Z; Liu M
    Front Pharmacol; 2021; 12():732912. PubMed ID: 34867339
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China.
    Zhang X; Fan X; Zhang J; Jiang F; Wu Y; Yang B; Li X; Liu D
    Front Public Health; 2024; 12():1425734. PubMed ID: 39091529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
    Li W; Wan L; Zhang J
    Expert Rev Gastroenterol Hepatol; 2024 Jun; 18(6):293-301. PubMed ID: 38923910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.
    Li L; Liu X; Huang J; Liu Y; Huang L; Feng Y
    J Gastrointest Oncol; 2022 Feb; 13(1):40-48. PubMed ID: 35284115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
    Lin YT; Chen Y; Liu TX; Kuang F; Huang P
    Cancer Manag Res; 2021; 13():8219-8230. PubMed ID: 34754242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
    Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
    Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
    Liang X; Chen X; Li H; Li Y
    Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
    Kang S; Wang X; Pan Z; Liu H
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.
    Zheng Z; Lin J; Zhu H; Cai H
    Front Public Health; 2022; 10():893387. PubMed ID: 35774581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.
    Wei J; Xu K; Lin Y; Liu Q; Zhou C; Zhang P; Ma R; Zhang M; Zhang L; Li X
    Int J Clin Pharm; 2024 Oct; 46(5):1189-1199. PubMed ID: 38814514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302.
    Hara H; Satoh T; Kojima T; Tsushima T; Sunakawa Y; Okada M; Ding N; Wu H; Li L; Yu T; Barnes G; Kato K
    Esophagus; 2024 Apr; 21(2):102-110. PubMed ID: 38240916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
    Fang R; Wang S; Liu Y; Xu J
    Adv Ther; 2023 Mar; 40(3):1019-1030. PubMed ID: 36622553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Liu Y; Shao R
    Front Pharmacol; 2024; 15():1225076. PubMed ID: 38813103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
    Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
    Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Lin YT; Zhou CC; Xu K; Zhang MD; Li X
    Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.